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Due to Western Australia’s large geographic size and low rural population density few 
breast imaging diagnostic services are available outside the metropolitan area. BreastScreen 
WA offers population mammographic screening via fixed clinics in the metropolitan area 
and mobile clinics that visit country areas every two years. If an abnormality is suspected 
following mobile clinic screening, women undergo Step Down Assessment; diagnostic 
further views are performed at the mobile clinic and if a possibly significant abnormality 
persists, country women are referred to a Perth Metropolitan Breast Assessment Centre. 
The purpose of this retrospective cohort study was to determine if Step Down Assessment 
in country Western Australia offered women the same diagnostic effectiveness as screening 
and assessment in the metropolitan area. 
 
Methods 
The study used all screening episodes at BreastScreen WA between 1999 and 2008.  
Screening episodes from metropolitan and mobile clinics were compared according to the 
primary outcomes of cancer detection rates, recall and further investigations, cancer size, 
return to screen rates and interval cancers. 
 
Results 
Overall, the cancer detection rate per 1000 screening episodes was lower for the country 
program than the metropolitan program (3.07 (2.84-3.31) versus 7.04 (6.82-7.27)). The false 
negative (interval cancer) rate was lower for Step Down Assessment than for the 
metropolitan program. The size of cancers detected was the similar for both screening 
services. Return to screen rates were comparable between both groups.  
 
Conclusion 
The results indicate that the current service model is providing appropriate diagnostic 









BreastScreen WA has been part of the national BreastScreen Australia program since 1991 
(1). Only 30% of West Australians reside outside the metropolitan area and generally 
experience lower access to health-care services than their metropolitan counterparts (2). 
Due to Western Australia’s large geographic size and low rural population density few 
breast imaging diagnostic services are available outside the metropolitan area. Women 
residing in rural areas often have to travel hundreds of kilometres to access breast 
diagnostic services.   While the overall effectiveness of population mammographic screening 
in Western Australia has been demonstrated (3), the purpose of this study is to determine if 
women in country and metropolitan locations are benefiting to the same degree from the 
screening services offered by BreastScreen WA. 
BreastScreen WA offers population mammographic screening via fixed clinics in the 
metropolitan area and mobile clinics that visit country areas every two years (figure 2). If an 
abnormality is suspected following mobile clinic screening, women undergo Step Down 
Assessment; diagnostic further views are performed at the mobile clinic and if a possibly 
significant abnormality persists, country women are referred to a Perth Metropolitan Breast 
Assessment Centre (figure 1). 
Only NT and WA have a Step-Down Assessment programme. Other states and territories do 
have a mobile van, however women screened are sent straight to a metropolitan BAC for 
further investigation. In NSW, Victoria and Queensland some of the larger rural towns in 
each state have assessment centres. In South Australia all women have to go to Adelaide for 
mammographic screening. 
The BreastScreen WA program involves two view mammography performed by trained 
medical imaging technologists and interpreted independently by two radiologists (Figure 1). 
If the results are discordant, a third radiologist is consulted. If the mammogram is normal 
the woman returns to routine biennial screening. If the mammogram is possibly abnormal 
the woman is contacted for further assessment.  Metropolitan women may undergo 
assessment at a Breast Assessment Centre (BAC) where diagnostic further views (DFV), 
clinical examination, ultrasound, fine needle aspiration, core biopsy and diagnostic open 
biopsy are available. Rural women may also attend screening at metropolitan fixed clinic, 
and if an abnormality is detected, be invited to attend a BAC. Most rural women attend 
mammographic screening on the BreastScreen mobile van clinic and if an abnormality is 
suspected they undergo Step Down Assessment involving DFVs performed at the van. If a 
possibly significant abnormality persists on DFV country women are referred to a Perth 
metropolitan BAC. Alternatively both country and metropolitan women can opt out of the 
program and attend a GP for private referrals.  
 




This study includes all screening episodes for women who attended a BreastScreen WA 
clinic between 1999 and 2008. Women aged 50-69 years enrolled on the Western Australian 
electoral roll receive a letter of invitation to participate in the screening program. All women 
aged above 40 may also participate in the screening program however are not actively 
recruited. Women aged 50-69 residing in country areas participated in the BreastScreen 
program at a rate of 59.3% and metropolitan women at a rate of 56.5% in 2005, 




The electoral roll does not provide information on demographic details, comorbidities or 
previous cancers.  Women complete a standard information sheet at the time of screening 
including information on country of birth, language spoken at home, HRT use and previous 
breast cancer. No data is collected on menopausal status. The State Coordination Unit 
collects information regarding the outcome and treatment of all screen-detected 
abnormalities including those where the woman elects to have assessment conducted 
privately or at another public facility. 
Data was extracted from the BreastScreen database according to the clinic location of the 
first mammogram of a particular screening episode. Data from 1999-2008 was merged and 
evaluated. This data included the number of women screened, the number of women 
receiving DFVs, the number of women receiving further investigations, the number of 
invasive cancers detected, the size of detected cancers, the number of women returning to 
screen within 27 months and the number of interval cancers. An interval cancer is defined 
as “the number of invasive breast cancers detected in women screened through 
BreastScreen Australia that arise during an interval between two screening rounds, per 10 
000 women years.”(4) Only women aged 50-67 were included in the rescreen rate as only 
they remained in the target age group 27 months after their index screen. The screening 
interval of 27 months is used instead of the recommended 2 year interval to allow for 
potential delays in screening availability and data transfer. 
Women who attend for annual screening are included in the study. Rural women who 
screen annually with the program will have one of their screens at Perth, every two years. 
This will not affect the return to screen rate, interval cancer rate or cancer detection rates  





Outcomes of screening for country and metropolitan locations were compared for 
percentage of screens going on to DFVs and further investigations; cancer detection rate 
overall and among screens going on to DFV and further investigation; average cancer size; 
interval cancer rate; and return to screen within 27 months overall and among screens 
going on to DFV and further investigation. All rates are not age standardised. 
Interval cancers were identified by matching the names of women screened by 
BreastScreen WA with those listed on the Western Australian Cancer Registry. Cases are 
automatically matched by name, address and date of birth and then checked manually.  
Interval cancers from 1999-2007 were calculated in terms of women years at risk and 
include all women screened aged 50-69 years who at the time of screening were resident in 
the area in which they were screened and did not report a personal history of invasive 




The study included a total of 760 027 screening episodes. 71.8% of screening episodes took 
place at a metropolitan clinic and 28.2% at a rural location. 
Overall, the cancer detection per 1000 screening episodes was lower for the country 
program than the metropolitan program (3.07 (2.84-3.31) versus 7.04 (6.82-7.27)) (Table 1). 
Sensitivity of cancer detection at the metropolitan clinic was 0.91 and at the country clinic 
0.95. Sensitivity was calculated by dividing the number of cancers detected by the number 
of cancers detected plus the interval cancer rate.  
Conversely, the rate of cancer detection among women recalled for assessment after a DFV 
was 289.9 (271.2-308.5) per 1000 country screens (figure 1, group (j+k), stage 3 assessment) 
versus 185.8 (180.5-191.1) per 1000 metropolitan screens (figure 1, group (i)). Of those 
country women who had assessment following DFV, 71.8% underwent further work up at an 
affiliated BAC and 28.2% locally at a public or private hospital or radiology facility.  
Recall rates following a screening mammogram were comparable between country and 
metropolitan women (Table 2). A country woman recalled for assessment was more likely to 
have a DFV only and be returned to routine biennial screening (62.4%) than to be referred 
for additional investigations (37.6%). Conversely among metropolitan women recalled for 
assessment, 29.6% received a DFV only and 70.4% were referred for additional 
investigations. Country women recalled to the BreastScreen van for DFVs were less likely 
than metropolitan women to go on to additional diagnostic procedures (37.6% (36.4-38.4) 
versus 70.4% (69.9-70.9)). Of particular note, metropolitan women receive more 
ultrasounds than country women (54.2% vs. 26.4%). 
The average size of screen detected cancers was similar for country and metropolitan 
women. Cancers detected at the BAC following a metropolitan screening episode had an 
average size of 17.4 mm and those detected following a mobile clinic screening episode had 
an average size of 17.1mm. The percentage of cancers below 15mm in size was 57.8% (56.2-
59.4) in metropolitan women, 60.6% (56.3-64.8) in country women who had workup at the 
BAC. 
Interval cancer rates were lower among country women screened than metropolitan 
women screened. The interval cancer rate from 0-12 months per 10000 women years at risk 
was 0.16 (0.02-0.34) for country women and 0.70 (0.46-0.94) for metropolitan women. The 
interval cancer rate from 13-24 months per 10000 women years at risk was 0.54 (0.18-0.89) 
for country women and 0.76 (0.49-1.03) for metropolitan women. These rates are well 
below the BSA performance standard for this age group of < 7.5 interval cancers per 
10,000 women aged between 50-69. 
Rescreening participation rates within 27 months of the index screening episode were 
64.9% (64.7-65.1) among all country women and 68.3% (68.2-68.4) among all metropolitan 
women (Table 3). Fewer women who go on to more intensive assessment return to screen 
within 27 months, but these values are comparable between the country and metropolitan 




Breast cancer is the most common life threatening cancer diagnosed in Australian women 
(5). BreastScreen WA detects tumours that are smaller in size, display less lympho-vascular 
invasion, are of lower histological grade and have a higher incidence of DCIS than cancers 
detected in Western Australia women outside the program (3).  BreastScreen WA is the only 
state based program in Australia to undertake Step Down Assessment.  
The results of this study demonstrate that in terms of cancer detection accuracy, women in 
country and metropolitan locations are benefiting to the same degree from the screening 
and assessment processes. While rates of cancer detection are higher in metropolitan 
women than country women (7.04 per 1000 vs 3.07 per 1000), the authors believe this does 
not reflect cancers being missed by the Step Down Assessment process as evidenced by the 
lower rate of interval cancers among country women screened. It would appear that there is 
a lower incidence of breast cancer in country versus metropolitan Western Australian 
women. The National Breast and Ovarian Cancer Centre has recently noted that the 
incidence of breast cancer is significantly lower in women living in rural and remote regions, 
when compared with women living in metropolitan areas of Australia (6).  The BreastScreen 
Australia monitoring report(4) found that the incidence of invasive breast cancer from 2004-
2008 in women aged 50-69 years decreased with increasing level of remoteness from the 
metropolitan area nationally. There are various measures used to indicate the efficacy of a 
breast cancer screening program. The development of interval cancers in the 12 month time 
period following a negative screen is a particularly important performance indicator (4). The 
lower interval cancer rate among country women than metropolitan women supports the 
diagnostic effectiveness of the BreastScreen WA Screening and Step Down Assessment 
process.  
The reasons for the higher rate of breast cancer among the metropolitan women included in 
this study are currently unknown. Without data matching, underlying differences between 
country and metropolitan women in terms of age and menopausal status may be 
contributing to the differences in cancer detection rates between the two groups. Although 
an Australia wide study showed that country women were less likely than metropolitan 
women to participate in mammographic screening programs (7) this is not the case in 
Western Australia. BreastScreen WA data shows that metropolitan and country programs 
are achieving similar rates of participation within the target age range of 50-69 years (56.5% 
vs 59.3% in 2005) (1). The results of our study showed the average size of cancers detected 
at metropolitan and country clinics to be comparable.  
Country women are receiving fewer investigations overall without compromising cancer 
detection rates. This likely reflects the higher incidence of significant abnormalities present 
in metropolitan women who require more work up. It would appear that metropolitan 
women are being subjected to a degree of opportunistic screening ultrasound examinations 
while at the BAC. A formal economic analysis of the metropolitan and country programs has 
not been conducted and would provide valuable information regarding their comparative 
cost effectiveness. Previous research has suggested that high use of assessment 
investigations may increase anxiety associated with screening without conferring benefit in 
terms of accuracy of assessment (8, 9). Despite this consideration, rescreen participation 
rates are comparable between metropolitan and country women irrespective of how 
extensively they are investigated before being returned to the routine biennial screening 
schedule. This suggests that both groups are equally satisfied with the service provided to 
them; however, a qualitative study examining the attitudes of country and metropolitan 
West Australian women towards the Step Down Assessment and standard assessment 
procedures would provide more evidence on this matter. 
 
CONCLUSION 
This study described the Step Down Assessment process provided to country women by 
BreastScreen WA. The diagnostic effectiveness of Step Down Assessment was compared to 
that of the standard screening and assessment protocol offered to metropolitan women. 
The study found that Step Down Assessment lead to the detection of cancers at a 
comparable size to the standard metropolitan screening and assessment protocol and was 
associated with a lower false negative (interval cancer) rate. The lower cancer detection rate 
in rural versus metropolitan women was attributed to lower cancer incidence rates for rural 
versus metropolitan women in Australia (6).  These findings support the continuation of the 
Step Down program as an effective way to deliver breast cancer screening and assessment 
in country areas without the need for women to travel thousands of kilometres for 
assessment at a metropolitan clinic. 
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Table 1 – Cancer Detection Rates in women presenting to BreastScreen WA clinics in 
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Table 2 – Proportion of women recalled who received further investigations.   
 Metropolitan clinics Country Clinics 
Type of investigation Percent 
CI 
Rate of use 
CI 























































Table 3 – Percent of women at metropolitan and country BreastScreenWA clinics who 
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